Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Clin Transl Med. 2024 Jul;14(7):e1764. doi: 10.1002/ctm2.1764.
As one of the most prevalent digestive system tumours, colorectal cancer (CRC) poses a significant threat to global human health. With the emergence of immunotherapy and target therapy, the prognosis for the majority of CRC patients has notably improved. However, the subset of patients with BRAF exon 15 p.V600E mutation (BRAF) has not experienced remarkable benefits from these therapeutic advancements. Hence, researchers have undertaken foundational investigations into the molecular pathology of this specific subtype and clinical effectiveness of diverse therapeutic drug combinations. This review comprehensively summarised the distinctive molecular features and recent clinical research advancements in BRAF-mutant CRC. To explore potential therapeutic targets, this article conducted a systematic review of ongoing clinical trials involving patients with BRAF-mutant CRC.
作为最常见的消化系统肿瘤之一，结直肠癌（CRC）对全球人类健康构成了重大威胁。随着免疫疗法和靶向治疗的出现，大多数 CRC 患者的预后显著改善。然而，BRAF 外显子 15 p.V600E 突变（BRAF）的患者亚组并没有从这些治疗进展中获得显著的益处。因此，研究人员对这一特定亚型的分子病理学和不同治疗药物组合的临床疗效进行了基础研究。本综述全面总结了 BRAF 突变型 CRC 的独特分子特征和最新临床研究进展。为了探索潜在的治疗靶点，本文对正在进行的 BRAF 突变型 CRC 患者临床试验进行了系统回顾。
